Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Deferred Tax Assets: 2018-2021

  • China SXT Pharmaceuticals' Current Deferred Tax Assets fell 4.87% to $504,522 in Q3 2021 from the same period last year, while for Sep 2021 it was $504,522, marking a year-over-year decrease of 4.87%. This contributed to the annual value of $547,807 for FY2021, which is 7.28% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Current Deferred Tax Assets of $504,522 as of Q3 2021, which was down 7.90% from $547,807 recorded in Q1 2021.
  • In the past 5 years, China SXT Pharmaceuticals' Current Deferred Tax Assets registered a high of $547,807 during Q1 2021, and its lowest value of -$48,454 during Q3 2018.
  • Its 2-year average for Current Deferred Tax Assets is $523,330, with a median of $520,494 in 2020.
  • Data for China SXT Pharmaceuticals' Current Deferred Tax Assets shows a peak YoY increase of 7.28% (in 2021) and a maximum YoY decrease of 4.87% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows China SXT Pharmaceuticals' Current Deferred Tax Assets stood at -$48,454 in 2018, then reached $530,372 in 2020, then decreased by 4.87% to $504,522 in 2021.
  • Its last three reported values are $504,522 in Q3 2021, $547,807 for Q1 2021, and $530,372 during Q3 2020.